Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,126.90 | 2.50 | -0.03% |
CAC 40 | 7,692.82 | 18.04 | 0.24% |
DAX 40 | 23,769.11 | 172.13 | 0.73% |
Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
FTSE 100 | 9,214.86 | 6.65 | 0.07% |
HKSE | 25,618.72 | 200.74 | 0.79% |
NASDAQ | 21,700.39 | 7.30 | -0.03% |
Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
S&P 500 | 6,481.50 | 20.58 | -0.32% |
S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
SSE Composite Index | 3,826.84 | 14.33 | 0.38% |